CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.25: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.61%Above 5Y avg (0.39%)
Annual Rate
CNY 0.05Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Sep 23, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.83BCNY720.44M · vs all stocks (USD)
Trailing P/E
31.92xRevenue (TTM)
1.29BCNY193.15M · vs all stocks (USD)
Profit Margin
11.01%Beta
0.2770xvs all stocks
52-Week Change
-8.19%vs all stocks
Market Capitalization
4.83BCNY720.44M · vs all stocks (USD)
Enterprise Value
4.68BCNY698.00M · vs all stocks (USD)
Trailing P/E
31.92xForward P/E
15.96xPrice to Sales (TTM)
3.73xPrice to Book (MRQ)
1.94xEnterprise to Revenue
3.61xEnterprise to EBITDA
20.63xGross Margin
41.43%Profit Margin
11.01%Operating Margin
13.95%Return on Assets (TTM)
2.40%Return on Equity (TTM)
6.50%Revenue (TTM)
1.29BCNY193.15M · vs all stocks (USD)
Revenue per Share (TTM)
2.35CNYUpdated Sep 20, 2026Quarterly Revenue Growth
17.10%Gross Profit (TTM)
563.44MCNY84.08M · vs all stocks (USD)
EBITDA (TTM)
163.34MCNY24.37M · vs all stocks (USD)
Net Income (TTM)
142.52MCNY21.27M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
125.40%Operating Cash Flow (TTM)
233.31MCNY34.81M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-103.39MCNY-15.43M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0500CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.61%vs all stocks
5-Year Average Dividend Yield
0.39%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
158.45MCNYFY2025 · Dec 31, 2025Revenue
1.21BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
653.18MCNYFY2025 · Dec 31, 2025Gross Profit
552.10MCNYFY2025 · Dec 31, 2025Operating Income
102.23MCNY15.25M · vs all stocks (USD)
Pre-tax Income
108.51MCNYFY2025 · Dec 31, 2025Income Tax Expense
19.87MCNYFY2025 · Dec 31, 2025Net Income
88.65MCNYFY2025 · Dec 31, 2025EBIT
148.29MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
206.74MCNYFY2025 · Dec 31, 2025Research & Development
93.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
222.43MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
39.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
515.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
515.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
88.65MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.09MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
14.11MCNYFY2025 · Dec 31, 2025Free Cash Flow
-204.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
231.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
88.65MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-105.11MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-218.86MCNYFY2025 · Dec 31, 2025Net Acquisitions
-870.00KCNYFY2025 · Dec 31, 2025Sale of Investments
24.43MCNYFY2025 · Dec 31, 2025Other Investing Activity
-52.09MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-247.38MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
518.68MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-361.89MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-37.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.04MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
107.34MCNYFY2025 · Dec 31, 2025Shares Outstanding
581.69MSharesUpdated Sep 20, 2026Float Shares
445.84MSharesUpdated Sep 20, 2026% Held by Insiders
28.39%vs all stocks
% Held by Institutions
0.70%vs all stocks
Total Cash (MRQ)
882.32MCNY131.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.52CNYUpdated Sep 20, 2026Total Debt (MRQ)
567.65MCNY84.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2135xCurrent Ratio (MRQ)
2.64xBook Value per Share (MRQ)
4.29CNYUpdated Sep 20, 2026Total Assets
3.35BCNY499.52M · vs all stocks (USD)
Total Current Assets
1.38BCNYFY2025 · Dec 31, 2025Total Liabilities
930.36MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.97BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
355.97MCNYFY2025 · Dec 31, 2025Total Current Liabilities
574.39MCNYFY2025 · Dec 31, 2025Cash
252.85MCNYFY2025 · Dec 31, 2025Cash Equivalents
42.58MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
295.44MCNYFY2025 · Dec 31, 2025Other Short-term Investments
379.75MCNYFY2025 · Dec 31, 2025Accounts Receivable
254.20MCNYFY2025 · Dec 31, 2025Inventory
383.75MCNYFY2025 · Dec 31, 2025Accounts Payable
214.38MCNYFY2025 · Dec 31, 2025Short-term Debt
265.40MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.13MCNYFY2025 · Dec 31, 2025Long-term Debt
250.95MCNYFY2025 · Dec 31, 2025Common Stock (Book)
562.87MCNYFY2025 · Dec 31, 2025Retained Earnings
829.82MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.42BCNY360.69M · vs all stocks (USD)
52-Week Low
7.08CNYUpdated Sep 20, 202652-Week High
11.38CNYUpdated Sep 20, 202652-Week Change
-8.19%vs all stocks
Beta
0.2770xvs all stocks
50-Day MA
8.37CNYUpdated Sep 20, 2026200-Day MA
8.97CNYUpdated Sep 20, 2026Avg 10-Day Volume
18.48MSharesUpdated Sep 20, 2026Avg 30-Day Volume
34.25MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.2600CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.25: safe zoneNotable
Altman Z-Score: 4.25
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule